ConductScience.org, home

Paper34736731

Rivaroxaban Monotherapy in Patients With Atrial Fibrillation After Coronary Stenting: Insights From the AFIRE Trial.

Matoba T and 12 others. JACC Cardiovasc Interv, 2021. Cited by 20 papers, by iCite.

Cite this record

ConductScience Library. Rivaroxaban Monotherapy in Patients With Atrial Fibrillation After Coronary Stenting: Insights From the AFIRE Trial. Papers, record 34736731. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/34736731

Download JSON
Disease
coronary artery disorder241 drugs
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Rivaroxaban Monotherapy in Patients With Atrial Fibrillation After Coronary Stenting: Insights From the AFIRE Trial.
PubMed
Journal
JACC Cardiovasc Interv
PubMed
Year
2021
PubMed
Publication types
Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
20
iCite
Relative citation ratio, by iCite
1.15
iCite
Revised in PubMed
2026-05-18
PubMed

Authors13

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Matoba TTetsuya
2Yasuda SSatoshi
3Kaikita KKoichi
4Akao MMasaharu
5Ako JJunya
6Nakamura MMasato
7Miyauchi KKatsumi
8Hagiwara NNobuhisa
9Kimura KKazuo
10Hirayama AAtsushi
11Matsui KKunihiko
12Ogawa HHisao
13AFIRE InvestigatorsGroup

Source PubMed

Download CSV of authors

Topics8

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Atrial FibrillationMajor topic
RivaroxabanMajor topic
Coronary Artery Disease
Factor Xa Inhibitors
Hemorrhage
Humans
Stents
Treatment Outcome

Source PubMed

Download CSV of topics

Trials1

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's record
NCT02642419Atrial Fibrillation and Ischemic Events With Rivaroxaban in Patients With Stable Coronary Artery Disease StudyDerived from the trialYes

Source ClinicalTrials.gov

Download CSV of trials

Comments and corrections1

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

KindPMIDTitleIn Papers
Comment in34736732Oral Anticoagulant Alone for Patients With AF and a Prior Stent: Is Less Always Best?https://conductscience.org/library/papers/34736732

Source PubMed

Download CSV of comments and corrections

Cited by10

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 20 citations.

PMIDTitleJournalYearIn PapersSource
42796070Antithrombotic Therapy in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention.J Clin Med2026https://conductscience.org/library/papers/42796070PubMed
41307698The role of rivaroxaban in the management of coronary artery disease: an overview of five landmark clinical trials.Naunyn Schmiedebergs Arch Pharmacol2026https://conductscience.org/library/papers/41307698PubMed
40802193Age-Stratified Effect of Rivaroxaban Monotherapy for Atrial Fibrillation in Stable Coronary Artery Disease: A Post Hoc Analysis of the AFIRE Randomized Clinical Trial.JAMA Cardiol2025https://conductscience.org/library/papers/40802193PubMed
40524851JCS/JHRS 2024 Guideline Focused Update on Management of Cardiac Arrhythmias.J Arrhythm2025https://conductscience.org/library/papers/40524851PubMed
38043043
2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.
J Am Coll Cardiol2024https://conductscience.org/library/papers/38043043PubMed
38033089
2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.
Circulation2024https://conductscience.org/library/papers/38033089PubMed
37435100Temporal Trends in Antithrombotic Therapy for Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention From 2014 to 2022 in Japan.Circ Rep2023https://conductscience.org/library/papers/37435100PubMed
36072876Net clinical benefit of antithrombotic therapy for atrial fibrillation patients with stable coronary artery disease.Front Cardiovasc Med2022https://conductscience.org/library/papers/36072876PubMed
35683397Antithrombotic Therapy in Elderly Patients with Acute Coronary Syndromes.J Clin Med2022https://conductscience.org/library/papers/35683397PubMed
35663586ANMCO position paper on antithrombotic treatment of patients with atrial fibrillation undergoing intracoronary stenting and/or acute coronary syndromes.Eur Heart J Suppl2022https://conductscience.org/library/papers/35663586PubMed

Download CSV of cited by

Drugs1

The drugs whose trials, in the Pipelines release, list the paper.

DrugChEMBL IDThe trials list it asTrialsIn Drugs and targets
RIVAROXABANCHEMBL198362Derived from the trial1https://conductscience.org/library/drugs/CHEMBL198362

Source ChEMBL

Download CSV of drugs

Data1

The data bank entries PubMed's record names. Trial numbers are under Trials.

Data bankAccession
UMIN-CTRUMIN000016612

Source PubMed

Download CSV of data

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • References
  • Genes

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/34736731

GET https://conductscience.org/api/papers/v1/34736731/authors